Cordonnier A M, Fuchs R P
UPR9003 du CNRS, Cancérogenèse et Mutagenèse Moléculaire et Structurale, ESBS et IRCAD, Strasbourg, France.
Mutat Res. 1999 Oct 22;435(2):111-9. doi: 10.1016/s0921-8777(99)00047-6.
Individuals with Xeroderma pigmentosum (XP) syndrome have a genetic predisposition to sunlight-induced skin cancer. Genetically different forms of XP have been identified by cell fusion. Cells of individuals expressing the classical form of XP (complementation groups A through G) are deficient in the nucleotide excision repair (NER) pathway. In contrast, the cells belonging to the variant class of XP (XPV) are NER-proficient and are only slightly more sensitive than normal cells to the killing action of UV light radiation. The XPV fibroblasts replicate damaged DNA generating abnormally short fragments either in vivo [A.R. Lehmann, The relationship between pyramidine dimers and replicating DNA in UV-irradiated human fibroblasts, Nucleic Acids Res. 7 (1979) 1901-1912; S.D. Park, J.E. Cleaver, Postreplication repair: question of its definition and possible alteration in Xeroderma pigmentosum cell strains, Proc. Natl. Acad. Sci. U.S.A. 76 (1979) 3927-3931.] or in vitro [S.M. Cordeiro, L.S. Zaritskaya, L.K. Price, W.K. Kaufmann, Replication fork bypass of a pyramidine dimer blocking leading strand DNA synthesis, J. Biol. Chem. 272 (1997) 13945-13954; D.L. Svoboda, L.P. Briley, J.M. Vos, Defective bypass replication of a leading strand cyclobutane thymine dimer in Xeroderma pigmentosum variant cell extracts, Cancer Res. 58 (1998) 2445-2448; I. Ensch-Simon, P.M. Burgers, J.S. Taylor, Bypass of a site-specific cis-syn thymine dimer in an SV40 vector during in vitro replication by HeLa and XPV cell-free extracts, Biochemistry 37 (1998) 8218-8226.], suggesting that in XPV cells, replication has an increased probability of being blocked at a lesion. Furthermore, extracts from XPV cells were found to be defective in translesion synthesis [A. Cordonnier, A.R. Lehmann, R.P.P. Fuchs, Impaired translesion synthesis in Xeroderma pigmentosum variant extracts, Mol. Cell. Biol. 19 (1999) 2206-2211.]. Recently, Masutani et al. [C. Masutani, M. Araki, A. Yamada, R. Kusomoto, T. Nogimori, T. Maekawa, S. Iwai, F. Hanaoka, Xeroderma pigmentosum variant (XP-V) correcting protein from HeLa cells has a thymine dimer bypass DNA polymerase activity, EMBO J. 18 (1999) 3491-3501.] have shown that the XPV defect can be corrected by a novel human DNA polymerase, homologue to the yeast DNA polymerase eta, which is able to replicate past cyclobutane pyrimidine dimers in DNA templates. This review focuses on our current understanding of translesion synthesis in mammalian cells whose defect, unexpectedly, is responsible for the hypermutability of XPV cells and for the XPV pathology.
患有着色性干皮病(XP)综合征的个体具有遗传易感性,易患阳光诱发的皮肤癌。通过细胞融合已鉴定出遗传上不同形式的XP。表达经典形式XP(互补组A至G)的个体的细胞在核苷酸切除修复(NER)途径中存在缺陷。相比之下,属于XP变异型(XPV)的细胞NER功能正常,并且对紫外线辐射的杀伤作用仅比正常细胞稍敏感。XPV成纤维细胞在体内[A.R. 莱曼,紫外线照射的人成纤维细胞中嘧啶二聚体与复制DNA之间的关系,《核酸研究》7 (1979) 1901 - 1912;S.D. 帕克,J.E. 克利弗,复制后修复:其定义问题以及着色性干皮病细胞株中可能的改变,《美国国家科学院院刊》76 (1979) 3927 - 3931。]或体外[S.M. 科尔德罗,L.S. 扎里茨卡娅,L.K. 普赖斯,W.K. 考夫曼,嘧啶二聚体对前导链DNA合成的阻断的复制叉旁路,《生物化学杂志》272 (1997) 13945 - 13954;D.L. 斯沃博达,L.P. 布里利,J.M. 沃斯,着色性干皮病变异型细胞提取物中前导链环丁烷胸腺嘧啶二聚体的缺陷性旁路复制,《癌症研究》58 (1998) 2445 - 2448;I. 恩施 - 西蒙,P.M. 伯格尔斯,J.S. 泰勒,HeLa和XPV无细胞提取物在体外复制期间SV40载体中位点特异性顺式 - 反式胸腺嘧啶二聚体的旁路,《生物化学》37 (1998) 8218 - 8226。]复制受损DNA,产生异常短的片段,这表明在XPV细胞中,复制在损伤处被阻断的可能性增加。此外,发现XPV细胞的提取物在跨损伤合成方面存在缺陷[A. 科尔多尼耶,A.R. 莱曼 R.P.P. 富克斯,着色性干皮病变异型提取物中跨损伤合成受损,《分子细胞生物学》19 (1999) 2206 - 2211。]。最近,益谷等[C. 益谷,M. 荒木,A. 山田,R. 久宗本,T. 野木守,T. 前川,S. 岩井,F. 花冈,来自HeLa细胞的着色性干皮病变异型(XP - V)校正蛋白具有胸腺嘧啶二聚体旁路DNA聚合酶活性,《欧洲分子生物学组织杂志》18 (1999) 3491 - 3501。]表明,XPV缺陷可以通过一种新型人类DNA聚合酶来校正,该酶与酵母DNA聚合酶eta同源,能够复制通过DNA模板中的环丁烷嘧啶二聚体。本综述重点关注我们目前对哺乳动物细胞中跨损伤合成的理解,其缺陷出乎意料地导致了XPV细胞的高突变性和XPV病理学。